Immunovant Valuation Multiples

Immunovant Overview

About Immunovant

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Founded

2018

HQ

Employees

362

Website

immunovant.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($489M)

EV

$5B

Valuation Multiples

Multiples.vc

Start free trial

Immunovant Financials

Immunovant reported last 12-month revenue of — and negative EBITDA of ($489M).

In the same LTM period, Immunovant generated ($71K) in gross profit, ($489M) in EBITDA losses, and had net loss of ($477M).

Immunovant P&L

In the most recent fiscal year, Immunovant reported revenue of — and EBITDA of ($426M).

Immunovant expects next 12-month revenue of XXX and NTM EBITDA of XXX

Immunovant Stock Performance

Immunovant has current market cap of $6B, and enterprise value of $5B.

Immunovant's stock price is $29.30.

Immunovant Valuation Multiples

Immunovant trades at (10.7x) EV/EBITDA.

Immunovant Financial Valuation Multiples

As of April 18, 2026, Immunovant has market cap of $6B and EV of $5B.

Equity research analysts estimate Immunovant's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immunovant has a P/E ratio of (12.5x).

Immunovant Margins & Growth Rates

Immunovant's revenue in the last fiscal year grew by —.

Immunovant's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.

Immunovant Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Immunovant M&A Activity

Immunovant acquired XXX companies to date.

Last acquisition by Immunovant was on XXXXXXXX, XXXXX. Immunovant acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Immunovant Investment Activity

Immunovant invested in XXX companies to date.

Immunovant made its latest investment on XXXXXXXX, XXXXX. Immunovant invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).